281 related articles for article (PubMed ID: 32623581)
1. A multidisciplinary consensus on the morphological and functional responses to immunotherapy treatment.
Leon-Mateos L; Garcia-Velloso MJ; García-Figueiras R; Rodriguez-Moreno JF; Vercher-Conejero JL; Sánchez M; Perez Gracia JL; Simo-Perdigo M; Gorospe L
Clin Transl Oncol; 2021 Mar; 23(3):434-449. PubMed ID: 32623581
[TBL] [Abstract][Full Text] [Related]
2. [Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology].
Ferreirós J; Cabeza B; Gayete Á; Sánchez M; Torres MI; Cobo M; Isla D; Puente J; Reguart N; de Castro J
Radiologia; 2015; 57(1):66-78. PubMed ID: 25530188
[TBL] [Abstract][Full Text] [Related]
3. Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology.
de Castro J; Cobo M; Isla D; Puente J; Reguart N; Cabeza B; Gayete A; Sánchez M; Torres MI; Ferreirós J
Clin Transl Oncol; 2015 Jan; 17(1):11-23. PubMed ID: 25373531
[TBL] [Abstract][Full Text] [Related]
4. Endocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE) and Italian Society of Pharmacology (SIF) multidisciplinary group.
Zatelli MC; Faggiano A; Argentiero A; Danesi R; D'Oronzo S; Fogli S; Franchina T; Giorgino F; Marrano N; Giuffrida D; Gori S; Marino G; Mazzilli R; Monami M; Montagnani M; Morviducci L; Natalicchio A; Ragni A; Renzelli V; Russo A; Sciacca L; Tuveri E; Aimaretti G; Avogaro A; Candido R; Di Maio M; Silvestris N; Gallo M
Cancer Treat Rev; 2024 May; 126():102734. PubMed ID: 38604051
[TBL] [Abstract][Full Text] [Related]
5. Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer.
Provencio M; Carcereny E; Artal Á
Clin Transl Oncol; 2019 Nov; 21(11):1464-1471. PubMed ID: 30903517
[TBL] [Abstract][Full Text] [Related]
6. Multidisciplinary management of liver metastases in patients with colorectal cancer: a consensus of SEOM, AEC, SEOR, SERVEI, and SEMNIM.
Vera R; González-Flores E; Rubio C; Urbano J; Valero Camps M; Ciampi-Dopazo JJ; Orcajo Rincón J; Morillo Macías V; Gomez Braco MA; Suarez-Artacho G
Clin Transl Oncol; 2020 May; 22(5):647-662. PubMed ID: 31359336
[TBL] [Abstract][Full Text] [Related]
7. Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM).
Gonzalez-Cao M; Puertolas T; Riveiro M; Muñoz-Couselo E; Ortiz C; Paredes R; Podzamczer D; Manzano JL; Molto J; Revollo B; Carrera C; Mateu L; Fancelli S; Espinosa E; Clotet B; Martinez-Picado J; Cerezuela P; Soria A; Marquez I; Mandala M; Berrocal A;
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33782108
[TBL] [Abstract][Full Text] [Related]
8. SEOM/SERAM consensus statement on radiological diagnosis, response assessment and follow-up in colorectal cancer.
García-Carbonero R; Vera R; Rivera F; Parlorio E; Pagés M; González-Flores E; Fernández-Martos C; Corral MÁ; Bouzas R; Matute F
Clin Transl Oncol; 2017 Feb; 19(2):135-148. PubMed ID: 27206566
[TBL] [Abstract][Full Text] [Related]
9. Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy.
Mushti SL; Mulkey F; Tang S; Singh H; Lemery SJ; Goldberg KB; Sridhara R; Keegan P; Kluetz PG; Pazdur R; Theoret MR; Beaver JA
Curr Oncol Rep; 2020 Aug; 22(11):116. PubMed ID: 32851542
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy and the role of imaging.
Carter BW; Bhosale PR; Yang WT
Cancer; 2018 Jul; 124(14):2906-2922. PubMed ID: 29671876
[TBL] [Abstract][Full Text] [Related]
11. A real-world data of Immune checkpoint inhibitors in solid tumors from India.
Noronha V; Abraham G; Patil V; Joshi A; Menon N; Mahajan A; Janu A; Jain S; Talreja VT; Kapoor A; Kumar Singh G; Khaddar S; Gupta K; Rathinasamy N; Srinivas S; Agrawal A; Ventrapati P; Prabhash K
Cancer Med; 2021 Mar; 10(5):1525-1534. PubMed ID: 33591635
[TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M
Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663
[TBL] [Abstract][Full Text] [Related]
13. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
[TBL] [Abstract][Full Text] [Related]
14. How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
Denis M; Duruisseaux M; Brevet M; Dumontet C
Front Immunol; 2020; 11():492. PubMed ID: 32265935
[TBL] [Abstract][Full Text] [Related]
15. Atypical patterns of response and progression in the era of immunotherapy combinations.
Ferrara R; Matos I
Future Oncol; 2020 Aug; 16(23):1707-1713. PubMed ID: 32687405
[TBL] [Abstract][Full Text] [Related]
16. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.
Kamat AM; Bellmunt J; Galsky MD; Konety BR; Lamm DL; Langham D; Lee CT; Milowsky MI; O'Donnell MA; O'Donnell PH; Petrylak DP; Sharma P; Skinner EC; Sonpavde G; Taylor JA; Abraham P; Rosenberg JE
J Immunother Cancer; 2017 Aug; 5(1):68. PubMed ID: 28807024
[TBL] [Abstract][Full Text] [Related]
17. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
Puzanov I; Diab A; Abdallah K; Bingham CO; Brogdon C; Dadu R; Hamad L; Kim S; Lacouture ME; LeBoeuf NR; Lenihan D; Onofrei C; Shannon V; Sharma R; Silk AW; Skondra D; Suarez-Almazor ME; Wang Y; Wiley K; Kaufman HL; Ernstoff MS;
J Immunother Cancer; 2017 Nov; 5(1):95. PubMed ID: 29162153
[TBL] [Abstract][Full Text] [Related]
18. Imaging of tumour response to immunotherapy.
Dromain C; Beigelman C; Pozzessere C; Duran R; Digklia A
Eur Radiol Exp; 2020 Jan; 4(1):2. PubMed ID: 31900689
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy and the Interventional Oncologist: Challenges and Opportunities-A Society of Interventional Oncology White Paper.
Erinjeri JP; Fine GC; Adema GJ; Ahmed M; Chapiro J; den Brok M; Duran R; Hunt SJ; Johnson DT; Ricke J; Sze DY; Toskich BB; Wood BJ; Woodrum D; Goldberg SN
Radiology; 2019 Jul; 292(1):25-34. PubMed ID: 31012818
[TBL] [Abstract][Full Text] [Related]
20. SEOM clinical guidelines for the treatment of head and neck cancer (2020).
Mesia R; Iglesias L; Lambea J; Martínez-Trufero J; Soria A; Taberna M; Trigo J; Chaves M; García-Castaño A; Cruz J
Clin Transl Oncol; 2021 May; 23(5):913-921. PubMed ID: 33635468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
